Skip to main content
Clinical Trials/ITMCTR2000003734
ITMCTR2000003734
Recruiting
Phase 1

The Clinical and Mechanism Study on the Effect of Yiqi Yangyin Decotion (YQYYD) on Prevention for Patients with Early Stage Lung Cancer

onghua Hospital, Shanghai University of Traditional Chinese Medicine0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
onghua Hospital, Shanghai University of Traditional Chinese Medicine
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
onghua Hospital, Shanghai University of Traditional Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • (1\) Patients with stage I lung cancer who met the diagnostic criteria of primary lung cancer and were confirmed by histopathology or cytology included adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma and large cell carcinoma;
  • (2\) ground glass nodule (GGN) was found on CT scan, which indicated that it was adenocarcinoma in situ (AIS) or minimally invasive adenocarcinoma (MIA) (mainly judged by size and density), with an average diameter of \> 6 Mm, generally not exceeding 12mm, or CT scan revealed clear nodules of the same type before operation, mainly with ground glass nodules (solid nodules need more strict diagnosis and exclusion);
  • (3\) syndrome differentiation of Qi and yin deficiency by TCM;
  • (4\) 6 months or more after untreated or previous inhalation of budesonide;
  • (5\) heart, liver, kidney and blood tests were all in normal range.
  • (6\) Sign informed consent.

Exclusion Criteria

  • (1\) Patients with other primary malignant tumors;
  • (2\) Patients with serious heart, liver and kidney diseases and severe functional disorders;
  • (3\) Pregnant or lactating women;
  • (4\) Mental or cognitive disorders that affect the judgment of this study;
  • (5\) Those who are participating in other drug trials;
  • (6\) Those who are allergic to the drugs in this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials